SLV logo

Selvita S.A. Stock Price

WSE:SLV Community·zł681.0m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 9 Fair Values set on narratives written by author

SLV Share Price Performance

zł37.10
-18.10 (-32.79%)
zł37.10
-18.10 (-32.79%)
Price zł37.10

SLV Community Narratives

There are no narratives available yet.

Snowflake Analysis

Reasonable growth potential and fair value.

2 Risks
2 Rewards

Selvita S.A. Key Details

zł373.9m

Revenue

zł76.4m

Cost of Revenue

zł297.5m

Gross Profit

zł297.0m

Other Expenses

zł465.0k

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
0.025
79.56%
0.12%
33.2%
View Full Analysis

About SLV

Founded
2007
Employees
969
CEO
Boguslaw Sieczkowski
WebsiteView website
selvita.com

Selvita S.A. operates as a contract research organization worldwide. The company offers drug discovery services in the areas of AI-driven drug discovery, antibody drug discovery, structural biology, recombinant protein production, assay development and screening, computer-aided drug design, medicinal and synthetic chemistry, scale-up, ADME/DMPK, in vitro and In Vivo pharmacology, translational research, and toxicology. It also develops drugs for therapeutic areas, such as oncology, infectious diseases, immunology, neurology, respiratory, and other. In addition, the company provides drug development services, including formulation development; CMC analytical support; stability and shelf-life determination; clinical supply/GMP manufacturing; small molecules bioanalysis; drug substance and product; and biologics and biosimilars bioanalysis services. Further, it offers research and development services in the areas of agrochemistry analytical support, and flavor and fragrance chemistry. The company was formerly known as Selvita CRO S.A. and changed its name to Selvita S.A. in October 2019. Selvita S.A. was founded in 2007 and is based in Kraków, Poland.

Recent SLV News & Updates

Recent updates

No updates